logo
Share SHARE
FONT-SIZE Plus   Neg

Ennis To Buy Assets & Business Of PrintXcel And Printegra From Cenveo

Ennis, Inc. (EBF) said Monday that it has agreed to buy certain assets of Cenveo's document business including the manufacturing facilities branded under the names PrintXcel and Printegra.

Sales from both businesses are about $80 million annually. The PrintXcel facilities are located in Visalia, California; Toledo, Ohio; Clarkesville, Tennessee and Fairhope, Alabama. The Printegra facilities are located in Livermore, California; Arlington, Texas; Smyrna, Georgia; Indianapolis, Indiana; Fairport, New York; and Greensboro, North Carolina, with a sales office in Jaffrey, NH.

Trade liabilities were assumed in the deal, which is expected to close during February.

The operations will continue to operate under their respective trade names of PrintXcel and Printegra, Ennis said and added that it will continue to manufacture and market the pressure seal product line under the VersaSeal brand name. Substantially all of PrintXcel's and Printegra's employees will be offered positions with Ennis' new operation.

Ennis expects the acquisition to be accretive to its earnings in the first full year of operations.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of International Consolidated Airlines Group S.A. were gaining around 3 percent in London trading after the airline reported Friday higher profit in its second quarter, benefited by higher passenger revenues, despite weak cargo revenues. The company now expects low double digit percentage growth in pre-exceptional operating profit in 2016. Swiss banking giant UBS Group AG reported Friday a 14 percent decline in second quarter profit with weakness in net interest income. Looking ahead, the company said the difficult conditions continue to persist, yet the firm is well positioned to benefit from even a moderate improvement in conditions. UBS shares were gaining around 3 percent in the morning trading in Zurich. We are well into the third quarter and past the middle of the year and it is time to take stock of regulatory decisions awaiting some biotech stocks in August. Despite the uncertain macroeconomic environment, the markets have run up, with the S&P 500 Index making new highs session after session. Valuation concerns may keep traders at bay. However, the biotech space is a different cup of tea.
comments powered by Disqus
Follow RTT